Developer of MRI-guided, laser-based cancer treatments appoints John E. Schellhorn president, CEO and board member, firm says April 17. He succeeds James Duncan, who is retiring. Schellhorn will guide Monteris’ continuing development and commercialization of its NeuroBlate System, an MRI-guided, focused ablation device for treating brain tumors. The device, formerly called AutoLITT, won a new technology add-on payment of $5,300 from CMS in 2010; the payment rate went into effect in October of that year. (See Also see "CMS Awards Monteris Add-On Payment For Tumor Ablation Catheter" - Medtech Insight, 9 August, 2010..)
Schellhorn most recently served as chief commercialization officer for Barrx Medical, which specialized in the treatment of Barrett’s esophagus and was acquired by Covidien earlier this year. (See A#01111128015].)...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?